Capricor Inc.
Clinical trials sponsored by Capricor Inc., explained in plain language.
-
Heart cell therapy shows promise for duchenne MD in major trial
Disease control OngoingThis Phase 3 trial tests a cell therapy called deramiocel (CAP-1002) in 106 boys and young men with Duchenne muscular dystrophy. Participants receive either the cell therapy or a placebo every 3 months for a year, then all can receive the therapy for another year. The goal is to …
Phase: PHASE3 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Hope for duchenne: new cell therapy shows promise in Long-Term trial
Disease control OngoingThis study tests the long-term safety and effectiveness of a cell therapy called deramiocel (CAP-1002) in people with Duchenne muscular dystrophy who completed the earlier HOPE-2 trial. Participants receive an infusion of deramiocel every 3 months for about 5 years, with the opti…
Phase: PHASE2 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC